Long-form guides, side-effect deep-dives, and protocol comparisons for men’s health. No paid posts. No “transform your life” copy. We write what we’d want to read before making a treatment decision — for ourselves or someone in our family. Browse by category, search by keyword, or read everything we’ve published.
Retatrutide produces greater peak weight loss than tirzepatide in clinical data — roughly 24.2% body weight reduction at 48 weeks versus tirzepatide's 22.5% at 72 weeks — but calling it "better" depends entirely on what a researcher or clinician means by that word.
Adults taking semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound) should target 1.2–1.6 grams of protein per kilogram of reference body weight per day — roughly double the standard dietary recommendation — to preserve lean mass during pharmacologically induced weight loss.
Both versions of Wegovy — the once-weekly subcutaneous injection and the once-daily oral tablet — produce clinically meaningful weight loss using the same active drug, semaglutide.
Ozempic is not the best weight-loss drug available in 2026 — it never really was, by design. It's a diabetes medication that happens to cause meaningful weight loss, and the landscape has moved well past it on both efficacy and indication.
Tirzepatide produces meaningfully greater fat loss than semaglutide in head-to-head and comparative data — roughly 20% body weight reduction versus 15% at peak doses — and that gap matters for men carrying significant visceral adiposity.
Berberine lowers blood sugar — but not like Ozempic does. The honest comparison: berberine is a modest, affordable metabolic adjunct; semaglutide is a potent, FDA-approved drug with proven cardiovascular outcomes.
Brain fog is not listed as an adverse effect in the FDA prescribing information for either Mounjaro or Zepbound — but that doesn't mean patients never experience it.
Retatrutide produces roughly twice the weight loss of Wegovy in clinical trials — approximately 24–29% body weight reduction versus 14.9% for semaglutide 2.4 mg weekly — making it the most potent obesity pharmacotherapy tested in a phase 3 setting to date.
Zepbound and compounded tirzepatide contain the same active molecule, but that's roughly where the equivalence ends. The practical differences — in quality assurance, dosing reliability, safety documentation, and cost — are substantial enough to matter clinically.
Brand-name Wegovy has a robust clinical record; compounded semaglutide is cheaper but carries real manufacturing and dosing risks that the FDA has formally documented.
Ready to start a protocol?
Connect with vetted online providers for TRT, GLP-1, ED treatment, and more.
